Drug profile · INN
teriflunomide
APO-TERIFLUNOMIDE
teriflunomide (APO-TERIFLUNOMIDE) is a dihydroorotate dehydrogenase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — teriflunomide
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- ORAL
- Patents
- 0
- Programs
- 9
- Data quality
- 0.89
Quick answer
teriflunomide (APO-TERIFLUNOMIDE) is a dihydroorotate dehydrogenase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Dihydroorotate dehydrogenase inhibitor
Primary target: Dihydroorotate dehydrogenase (quinone), mitochondrial
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is teriflunomide?
teriflunomide (APO-TERIFLUNOMIDE) is a dihydroorotate dehydrogenase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for teriflunomide?
APO-TERIFLUNOMIDE is a marketed brand name for teriflunomide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of teriflunomide?
teriflunomide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.